ArticleBMC infectious diseases2024
A comparative study of general and severe mycoplasma pneumoniae pneumonia in children.
Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Neutrophil-to-lymphocyte ratio for predicting disease severity and outcomes in children with Mycoplasma pneumoniae pneumonia: a systematic review and meta-analysis.BMC pulmonary medicine · 2026Pooled it
- Efficacy and safety of modified Xuanbai Chengqi Decoction as an adjunctive treatment for severe pneumonia: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- S100A8/A9 as a novel predictor for severe Mycoplasma pneumoniae pneumonia in children: A prospective observational study.Clinics (Sao Paulo, Brazil) · 2026Article
- Factors associated with in-hospital mortality and treatment withdrawal in mechanically ventilated children with severe pneumonia: a retrospective cohort study.Translational pediatrics · 2026Article
- High-Dimensional Immune Profiling Reveals Innate-Adaptive Rebalancing and Subpopulation Trajectories in Pediatric SevereDiagnostics (Basel, Switzerland) · 2026Article
- Clinical and laboratory features of pediatric Mycoplasma pneumoniae Pneumonia with viral versus bacterial co-infection.Italian journal of pediatrics · 2026Article
- Combined Serum Expression of lncRNA CBR3-AS1 and miR-3163: Prognostic Significance and Underlying Mechanism in Severe Pneumonia.The clinical respiratory journal · 2026Article
- Novel inflammatory biomarkers and disease severity in hospitalized children withTranslational pediatrics · 2026Article
- Routine admission biomarkers for identifying co-infection and stratifying severity in pediatric macrolide-resistantTranslational pediatrics · 2026Article
- Article
- Clinical characteristics, risk factors, and pathogen spectrum of mixed infections in children withMicrobiology spectrum · 2026Article
- Article
- Clinical characteristics and prognostic factors influencing respiratory syncytial virus pneumonia in children with atopy: a retrospective cohort study.Translational pediatrics · 2026Article
- Independent risk factors and predictive model for high hospitalization costs in children with Mycoplasma pneumoniae pneumonia.BMC pediatrics · 2026Article
- Risk factors and clinical characteristics of fulminant Mycoplasma pneumoniae pneumonia in children: a retrospective case‒control study.BMC infectious diseases · 2026Article
- Blood-based inflammatory parameters and machine learning models for mortality prediction in critically ill pediatric pneumonia: a retrospective cohort study.Translational pediatrics · 2026Article
- Comparison of severe and general Mycoplasma pneumoniae pneumonia in children: a targeted next-generation sequencing based study.BMC infectious diseases · 2026Article
- Epidemiological characteristics of Mycoplasma pneumoniae in hospitalized children before during and after the COVID-19 pandemic in xi'an China.Scientific reports · 2026Article
- Qingfei Tongluo Jiedu Formula Regulates M2 Macrophage Polarization via the Butyric Acid-GPR109A-MAPK Pathway for the Treatment ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Immune Dysregulation and Cytokine Profiling in AcuteMicroorganisms · 2026Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
objectivesThe increasing prevalence of severe Mycoplasma pneumoniae pneumonia (SMPP) poses a significant threat to the health of children. This study aimed to characterise and assess the outcomes in children with SMPP.
methodsWe retrospectively analysed children hospitalised for M. pneumoniae pneumonia (MPP) between January and December 2022. Retrospectively, demographic, clinical, underlying diseases, laboratory and radiological findings, and treatment outcomes were collected and analysed. Disease severity was defined as severe or general according to the Guideline for diagnosis and treatment of community-acquired pneumonia in children (2019 version).
resultsOver a 12-month observation period, 417 children with MPP were enrolled, 50.6% (211/417) of whom had SMPP, with the peak incidence observed in winter. Of the 211 children with SMPP, 210 were treated and discharged with improvement, while one child with congenital heart disease died of cardioembolic stroke. A significantly higher proportion of patients with SMPP had underlying diseases, extrapulmonary complications (myocardial and digestive system involvement), and bacterial co-infection. A total of 25 (12%) children with SMPP received mechanical ventilation. The median duration of mechanical ventilation was 3 days. All children were treated with macrolide antibiotic. A significantly higher proportion of patients with SMPP received antibiotic other than macrolides, methylprednisolone sodium succinate, intravenous immunoglobulin and anticoagulation, compared with patients with general MPP (GMPP). Children with SMPP had significantly higher levels of white blood cells, neutrophil percentage, C-reactive protein, procalcitonin, interferon-γ, interleukin (IL)-2, IL-5, IL-6, IL-8, IL-10 and significantly lower percentages of lymphocytes, monocytes, and natural killer cells, compared with GMPP group.
conclusionOur findings suggest that severely ill children have more pronounced inflammatory reaction and extrapulmonary complications. For effective management of children with SMPP, hormonal, prophylactic, anticoagulant therapy, as well as the use of antibiotics other than macrolides for bacterial co-infections, could be incorporated into treatment regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.